Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Decolonization of S. Aureus in Hemodialysis Patients
NCT02945722Phase 4Terminated
- Sponsor
- CHU Saint-Etienne
- Start
- Feb 2018
- Primary completion
- Oct 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mupirocin and chlorhexidine + cymenol gel in Staphylococcus aureus infection (2 arms), sponsored by CHU Saint-Etienne. Primary endpoint: S. aureus infection at 12 months. Started Feb 2018; status: terminated.
02
Drugs
mupirocinchlorhexidine + cymenol gel
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT02945722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02945722.